Form 4: Akero Therapeutics CSO Sells Shares for Tax Obligations Under Pre-Arranged Plan

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, reported the sale of 1,129 shares of common stock at a weighted-average price of $54.84 to cover tax withholding obligations.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported a transaction involving the company's common stock.
• The transaction, a sale of shares, occurred on June 18, 2025.
• A total of 1,129 shares of common stock were disposed of.
• The shares were sold at a weighted-average price of $54.84, with individual transaction prices ranging from $54.33 to $54.84.
• The sale was explicitly stated as a 'sell-to-cover' transaction, automatically executed to satisfy tax withholding obligations in connection with the vesting of restricted stock units, and was not at the discretion of Mr. Rolph.
• Following this transaction, Mr. Rolph beneficially owns 166,234 shares of Akero Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: The transaction is a routine 'sell-to-cover' for tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This is generally viewed as neutral to slightly positive due to its non-discretionary nature and transparency, indicating no change in management's underlying confidence.

Positives

• The sale was a non-discretionary 'sell-to-cover' transaction, specifically for tax withholding obligations related to restricted stock unit vesting, rather than a discretionary sale that might signal a lack of confidence.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-arranged and not a reaction to recent market events, which enhances transparency.

Negatives

• No direct negatives are identified as the sale was for tax purposes and not a discretionary divestment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares (1,129) by an officer for tax purposes is a routine event and is unlikely to have a material impact on the company's stock price or shareholder value.

Key Dates

Keywords

Akero Therapeutics, AKRO, Timothy Rolph, Chief Scientific Officer, CSO, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan